Source: streetinsider

Morphotek: Morphotek To Present Its Proprietary RESPECT Antibody-Drug Conjugate (ADC) Technology At The Upcoming Antibody Engineering & Therapeutics Conference In San Diego

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it will present its Residue-Specific Conjugation Technology (RESPECT) at the Antibody Engineering & Therapeutics conference being held December 11-15 at the Manchester Grand Hyatt in San Diego, California.

Read full article »
Morphotek's Competitors | Morphotek's News | Morphotek's Financials

March 31, 2023

NS Medical Devices

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect

The post Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regene... See more »

March 31, 2023

Drug Discovery and Development

XOMA acquires Ixinity's commercial payment and milestone rights in $9.6M

Biotech royalty aggregator XOMA (Nasdaq:XOMA) has acquired the commercial payment and part of the mil... See more »

March 31, 2023

Contract Pharma

XOMA Acquires IXINITY Asset from Aptevo Therapeutics

XOMA gets the full commercial payment stream and a portion of Aptevo's milestone rights for the Hemop... See more »
Morphotek's News
March 30, 2023Pharamceutical Technology

EC approves Regeneron's Libtayo along with chemotherapy for NSCLC

Libtayo is a complete human monoclonal antibody that targets the immune checkpoint receptor PD-1 on T... See more »
Morphotek's News
March 30, 2023MarketScreener

XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

(marketscreener.com) EMERYVILLE, Calif., March 30, 2023 -- XOMA Corporation , announced today it has ... See more »
Morphotek's News
March 30, 2023Bloomberg Law

Pfizer Moves Close to Deals Target With Seagen Buy, Lawyer Says

Pfizer Inc.'s deal-making goal is close to complete with its planned acquisition of cancer-drug maker... See more »

March 31, 2023

NS Medical Devices

Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect

The post Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regene... See more »

March 31, 2023

Drug Discovery and Development

XOMA acquires Ixinity's commercial payment and milestone rights in $9.6M

Biotech royalty aggregator XOMA (Nasdaq:XOMA) has acquired the commercial payment and part of the mil... See more »

March 31, 2023

Contract Pharma

XOMA Acquires IXINITY Asset from Aptevo Therapeutics

XOMA gets the full commercial payment stream and a portion of Aptevo's milestone rights for the Hemop... See more »
Morphotek's News
March 30, 2023Pharamceutical Technology

EC approves Regeneron's Libtayo along with chemotherapy for NSCLC

Libtayo is a complete human monoclonal antibody that targets the immune checkpoint receptor PD-1 on T... See more »
Morphotek's News
March 30, 2023MarketScreener

XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio

(marketscreener.com) EMERYVILLE, Calif., March 30, 2023 -- XOMA Corporation , announced today it has ... See more »
Morphotek's News
March 30, 2023Bloomberg Law

Pfizer Moves Close to Deals Target With Seagen Buy, Lawyer Says

Pfizer Inc.'s deal-making goal is close to complete with its planned acquisition of cancer-drug maker... See more »
Stay up-to-date with the latest news on Morphotek
Est. Annual Revenue
$25-100M
Agree?
Est. Employees
25-100
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Morphotek